Icu Medical Intrinsic Value Calculation – ICU MEDICAL Reports Third Quarter Earnings for FY2023 on November 6th
November 26, 2023
🌥️Earnings Overview
On November 6, 2023, ICU MEDICAL ($NASDAQ:ICUI) reported their third quarter of FY2023 earnings with total revenue of USD 553.3 million, representing a 7.5% decrease from the same period in the previous year. Despite this, net income saw an impressive increase of 154.8%, resulting in USD 7.2 million.
Share Price
According to the report, the company’s stock opened at $102.8 and closed at $102.0, indicating a slight decrease of 0.6% from the previous closing price of 102.6. This marks the fourth consecutive quarter of decline for ICU MEDICAL. The earnings report was met with mixed reactions from investors as the company’s revenue grew by 8% compared to the same quarter last year. This may have been due to the increase in expenses incurred from research and development.
Looking ahead, ICU MEDICAL is expecting to see a steady growth in their revenue as they continue to invest in new innovations and technologies. They are also aiming to reduce expenses and optimize operations in order to further improve their bottom line. While the current results are slightly disappointing, investors are still optimistic about the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icu Medical. More…
| Total Revenues | Net Income | Net Margin |
| 2.25k | -28.04 | -0.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icu Medical. More…
| Operations | Investing | Financing |
| 73.22 | -81.3 | -38.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icu Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.38k | 2.28k | 86.92 |
Key Ratios Snapshot
Some of the financial key ratios for Icu Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.1% | -21.9% | 1.5% |
| FCF Margin | ROE | ROA |
| -0.6% | 1.0% | 0.5% |
Analysis – Icu Medical Intrinsic Value Calculation
Our proprietary Valuation Line has calculated the intrinsic value of ICU MEDICAL share to be around $237.9. Currently, the stock is being traded at $102.0, which is 57.1% lower than the intrinsic value. This discrepancy presents an opportunity for investors to purchase ICU MEDICAL stock at a great price. GoodWhale recommends that investors take advantage of this situation and buy the stock for a potential future return on investment. More…
Peers
It operates in a highly competitive market that includes major competitors such as Ypsomed Holding AG, Coloplast A/S, and Cardiovascular Systems Inc. These companies all strive to provide the best quality products and services to meet the needs of their customers.
– Ypsomed Holding AG ($LTS:0QLQ)
Ypsomed Holding AG is a leading Swiss medical technology company that designs, develops, and manufactures healthcare products for delivery of drugs and other treatments. The company has a market capitalization of 2.34 billion as of 2022, reflecting the confidence of investors in the company’s potential and its ability to grow in the coming years. Ypsomed Holding AG also has a Return on Equity of 4.93%, which is a measure of the company’s profitability relative to its shareholders’ equity. This indicates that the company is using its resources efficiently and delivering value to its shareholders.
– Coloplast A/S ($LTS:0QBO)
Coloplast A/S is a Danish medical device company that develops, manufactures, and markets medical products and services worldwide. The company has a market cap of 183.14B as of 2022 and a Return on Equity (ROE) of 50.58%. The market cap is an indication of the overall size of the company and its potential to generate profits. A high ROE indicates that the company is able to generate a significant return on the invested capital, making it an attractive investment. Coloplast is known for its products and services in the areas of urology, continence care, ostomy care, and wound and skin care, which have helped to ensure the company’s continued success.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Cardiovascular Systems Inc is a medical device company that develops, manufactures, and markets innovative interventional treatment systems for peripheral and coronary artery disease. The company has a market cap of 576.3M as of 2022 and a Return on Equity of -9.45%. This indicates that the company is not generating enough profits to cover its costs, which is not a good sign for the investors. Despite this, the company continues to innovate and develop new products in order to improve its financial performance.
Summary
Investors have been keeping a close eye on ICU Medical‘s financial performance lately, with the company reporting its third quarter financial results for FY2023 on November 6. Total revenue for the quarter saw a 7.5% dip compared to the same period last year, but net income saw a whopping 154.8% jump, amounting to USD 7.2 million. Analysts view this as a positive sign, indicative of increased efficiency in the company’s operations and a better management of its balance sheet. Investors are thus optimistic about the company’s future prospects.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
